243 related articles for article (PubMed ID: 15175422)
1. Pharmacokinetics of erythromycin in rabbit corneas after single-dose infusion: role of P-glycoprotein as a barrier to in vivo ocular drug absorption.
Dey S; Gunda S; Mitra AK
J Pharmacol Exp Ther; 2004 Oct; 311(1):246-55. PubMed ID: 15175422
[TBL] [Abstract][Full Text] [Related]
2. Enhanced corneal absorption of erythromycin by modulating P-glycoprotein and MRP mediated efflux with corticosteroids.
Hariharan S; Gunda S; Mishra GP; Pal D; Mitra AK
Pharm Res; 2009 May; 26(5):1270-82. PubMed ID: 18958406
[TBL] [Abstract][Full Text] [Related]
3. P-Glycoprotein expression in human retinal pigment epithelium cell lines.
Constable PA; Lawrenson JG; Dolman DE; Arden GB; Abbott NJ
Exp Eye Res; 2006 Jul; 83(1):24-30. PubMed ID: 16530756
[TBL] [Abstract][Full Text] [Related]
4. Existence of a p-glycoprotein drug efflux pump in cultured rabbit conjunctival epithelial cells.
Saha P; Yang JJ; Lee VH
Invest Ophthalmol Vis Sci; 1998 Jun; 39(7):1221-6. PubMed ID: 9620082
[TBL] [Abstract][Full Text] [Related]
5. Influence of erythromycin on the pharmacokinetics of ximelagatran may involve inhibition of P-glycoprotein-mediated excretion.
Eriksson UG; Dorani H; Karlsson J; Fritsch H; Hoffmann KJ; Olsson L; Sarich TC; Wall U; Schützer KM
Drug Metab Dispos; 2006 May; 34(5):775-82. PubMed ID: 16455803
[TBL] [Abstract][Full Text] [Related]
6. Functional assessment of multiple P-glycoprotein (P-gp) probe substrates: influence of cell line and modulator concentration on P-gp activity.
Taub ME; Podila L; Ely D; Almeida I
Drug Metab Dispos; 2005 Nov; 33(11):1679-87. PubMed ID: 16093365
[TBL] [Abstract][Full Text] [Related]
7. Quinidine as a probe for the role of p-glycoprotein in the intestinal absorption and clinical effects of fentanyl.
Kharasch ED; Hoffer C; Altuntas TG; Whittington D
J Clin Pharmacol; 2004 Mar; 44(3):224-33. PubMed ID: 14973303
[TBL] [Abstract][Full Text] [Related]
8. Impact of P-glycoprotein on clopidogrel absorption.
Taubert D; von Beckerath N; Grimberg G; Lazar A; Jung N; Goeser T; Kastrati A; Schömig A; Schömig E
Clin Pharmacol Ther; 2006 Nov; 80(5):486-501. PubMed ID: 17112805
[TBL] [Abstract][Full Text] [Related]
9. Evasion of P-gp mediated cellular efflux and permeability enhancement of HIV-protease inhibitor saquinavir by prodrug modification.
Jain R; Agarwal S; Majumdar S; Zhu X; Pal D; Mitra AK
Int J Pharm; 2005 Oct; 303(1-2):8-19. PubMed ID: 16137847
[TBL] [Abstract][Full Text] [Related]
10. Amino acid prodrug of quinidine: an approach to circumvent P-glycoprotein mediated cellular efflux.
Patel M; Mandava NK; Pal D; Mitra AK
Int J Pharm; 2014 Apr; 464(1-2):196-204. PubMed ID: 24440401
[TBL] [Abstract][Full Text] [Related]
11. Molecular evidence and functional expression of a novel drug efflux pump (ABCC2) in human corneal epithelium and rabbit cornea and its role in ocular drug efflux.
Karla PK; Pal D; Quinn T; Mitra AK
Int J Pharm; 2007 May; 336(1):12-21. PubMed ID: 17156953
[TBL] [Abstract][Full Text] [Related]
12. Marked impact of P-glycoprotein on the absorption of TAK-427 in rats.
Takeuchi T; Nonaka M; Yoshitomi S; Higuchi T; Ebihara T; Maeshiba Y; Kawase M; Asahi S
Biopharm Drug Dispos; 2008 Sep; 29(6):311-23. PubMed ID: 18651556
[TBL] [Abstract][Full Text] [Related]
13. Modulation of P-glycoprotein transport activity in the mouse blood-brain barrier by rifampin.
Zong J; Pollack GM
J Pharmacol Exp Ther; 2003 Aug; 306(2):556-62. PubMed ID: 12721332
[TBL] [Abstract][Full Text] [Related]
14. In vitro-to-in vivo prediction of P-glycoprotein-based drug interactions at the human and rodent blood-brain barrier.
Hsiao P; Bui T; Ho RJ; Unadkat JD
Drug Metab Dispos; 2008 Mar; 36(3):481-4. PubMed ID: 18057117
[TBL] [Abstract][Full Text] [Related]
15. Effect of cyclosporine on drug transport and pharmacokinetics of nifedipine.
Dorababu M; Nishimura A; Prabha T; Naruhashi K; Sugioka N; Takada K; Shibata N
Biomed Pharmacother; 2009 Nov; 63(9):697-702. PubMed ID: 19819100
[TBL] [Abstract][Full Text] [Related]
16. The utility of in vitro data in making accurate predictions of human P-glycoprotein-mediated drug-drug interactions: a case study for AZD5672.
Elsby R; Gillen M; Butters C; Imisson G; Sharma P; Smith V; Surry DD
Drug Metab Dispos; 2011 Feb; 39(2):275-82. PubMed ID: 21075975
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.
Smith BJ; Doran AC; McLean S; Tingley FD; O'Neill BT; Kajiji SM
J Pharmacol Exp Ther; 2001 Sep; 298(3):1252-9. PubMed ID: 11504828
[TBL] [Abstract][Full Text] [Related]
18. Verapamil P-glycoprotein transport across the rat blood-brain barrier: cyclosporine, a concentration inhibition analysis, and comparison with human data.
Hsiao P; Sasongko L; Link JM; Mankoff DA; Muzi M; Collier AC; Unadkat JD
J Pharmacol Exp Ther; 2006 May; 317(2):704-10. PubMed ID: 16415090
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein.
Kumar S; Kwei GY; Poon GK; Iliff SA; Wang Y; Chen Q; Franklin RB; Didolkar V; Wang RW; Yamazaki M; Chiu SH; Lin JH; Pearson PG; Baillie TA
J Pharmacol Exp Ther; 2003 Mar; 304(3):1161-71. PubMed ID: 12604693
[TBL] [Abstract][Full Text] [Related]
20. Effects of lovastatin on the pharmacokinetics of verapamil and its active metabolite, norverapamil in rats: possible role of P-glycoprotein inhibition by lovastatin.
Hong SP; Chang KS; Koh YY; Choi DH; Choi JS
Arch Pharm Res; 2009 Oct; 32(10):1447-52. PubMed ID: 19898809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
